Blood Types
Hybridoma Technology
Blood Typing
Bone Marrow Sampling and Transplants
Tissue Transplantation
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jul 21, 2026

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
Published on: March 7, 2013
1Japanese Red Cross Central Blood Center, Tokyo.
The Japan Marrow Donor Program (JMDP) uses a two-step HLA typing process to match donors and recipients. Initial typing includes HLA-A and HLA-B serology and low-resolution HLA-DRB1 DNA typing. Final matching involves reconfirming HLA-A and HLA-B and using high-resolution HLA-DRB1 DNA typing. Class I DNA typing is performed for A2, A26, B39, and B61, which are common in the Japanese population. A retrospective study of 363 transplants is evaluating how matching or mismatching HLA class I and class II alleles affects survival. The study suggests that matching HLA-A and HLA-B alleles reduces the risk of acute GVHD and improves survival in unrelated marrow transplants.
Area of Science:
Background:
Understanding compatibility between donors and recipients is essential in bone marrow transplantation. Prior research has shown that HLA matching influences transplant outcomes. However, the specific impact of high-resolution typing in certain populations remains unclear. The Japanese population exhibits unique HLA allele frequencies. These variations may affect transplant success rates. No prior work had resolved the role of class I and class II allele matching in this context. This gap motivated the JMDP to analyze their registry data. Their aim is to assess how allele-level matching affects survival and complications.
Purpose Of The Study:
The JMDP seeks to evaluate the impact of HLA allele matching on transplant outcomes. Specifically, the study focuses on the Japanese donor-recipient population. The goal is to determine how class I and class II allele matching affects survival. The researchers propose that precise matching reduces complications. They also aim to identify which alleles are most critical. This work addresses a knowledge gap in transplant immunology. The findings may inform donor selection strategies. The study uses a retrospective design with 363 transplants.
Main Methods:
The JMDP uses a two-step HLA typing process for donors. Initial typing includes serological HLA-A and HLA-B. Low-resolution HLA-DRB1 DNA typing is also performed. Final matching involves reconfirming HLA-A and HLA-B serologically. High-resolution HLA-DRB1 DNA typing is added for accuracy. Class I DNA typing targets A2, A26, B39, and B61. These alleles are common in the Japanese population. A retrospective analysis is being conducted on 363 transplants.
Main Results:
Matching HLA-A and HLA-B alleles reduced the risk of acute GVHD. This effect was observed in unrelated marrow transplants. Survival rates improved with better allele-level matching. The study found that high-resolution typing is important. Class I alleles A2, A26, B39, and B61 show significant variability. Each can be divided into more than three subtypes. The JMDP is analyzing how these subtypes affect outcomes. The Ministry of Health and Welfare supported this research.
Conclusions:
The JMDP study suggests that precise HLA allele matching improves transplant outcomes. Acute GVHD risk decreases with better class I matching. Survival rates also benefit from this approach. The study highlights the importance of high-resolution typing. Class I alleles A2, A26, B39, and B61 are particularly relevant. The JMDP is continuing its analysis of 363 transplants. These findings may guide donor selection in Japan. The Ministry of Health and Welfare endorses this research direction.
Matching HLA-A and HLA-B alleles reduced the risk of acute GVHD and improved survival in unrelated marrow transplants.
Class I DNA typing is performed for A2, A26, B39, and B61 due to their high frequency and multiple subtypes in the Japanese population.
High-resolution HLA-DRB1 DNA typing is used for final matching to ensure accurate donor-recipient compatibility.
The study aims to assess how matching or mismatching HLA class I and class II alleles affects survival rates.
Since 1992, about 82,000 donors and 4,400 patients have been registered in the JMDP.
The JMDP uses a two-step process: initial serological and low-resolution typing, followed by reconfirmation and high-resolution typing for final matching.